Zimmer Biomet Holdings, Inc. (ZBH)

From the record

Zimmer Biomet Holdings, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Zimmer Biomet Holdings, Inc.'s 10 filed years say what it did: revenue went from $7.7 billion in fiscal 2016 to $8.2 billion in fiscal 2025, up 0.8% a year; it rose in 8 of 9 years; the deepest fall was 23% from fiscal 2019 to fiscal 2020; net income was positive in 8 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Zimmer Biomet Holdings, Inc.'s diluted share count shrank about 1.9% a year, and dividends and buybacks returned about 55% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 6 sales and 0 purchases of their own stock on the open market in the year to 2026-10-05 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Zimmer Biomet Holdings, Inc. earned about 6 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 25 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 45 cents per dollar of assets, and net share issuance: its share count shrank 2.6% over the year (the filed statements).

From the record

Zimmer Biomet Holdings, Inc.'s standing among 26 graded names in its industry family: revenue of $8.2 billion in fiscal 2025 ranks in the top 6% by size; a net margin of 8.6% ranks in the top 25%; revenue growth of 5.9% a year over the last 3 filed years ranks in the top 50% (its annual reports).

From the record

Zimmer Biomet Holdings, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Tornos, Ivan (Chairman, President and CEO, as filed), filing under that title since 2023-09-06, 3.2 years (top 50% of its family); the 20 officers and directors filing in the last fifteen months have been on the record a median of 6.5 years (top 41%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 20 people in charge now (top 32%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Zimmer Biomet Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $592 million against debt of $6.9 billion leaves -27.5% of its assets as net cash, bottom 13% of its family; cash from operations less capital spending is 17.9% of revenue (top 14%); a gross margin of 69.7% (top 18%); research spending of 5.6% of revenue (bottom 37%) (its annual report).

From the record

Zimmer Biomet Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 5.9% a year over the last three filed years against 0.8% over all 10, speeding up (top 26% of its family); the newest year grew 7.2% (top 38%); research spending grew 4.1% a year (bottom 44%); capital spending grew 6.1% a year (top 48%) (its annual reports). Zimmer Biomet Holdings, Inc. reported 4 product lines in fiscal 2025: Knees at $3.3 billion (40%), SET at $2.2 billion (26%), Hips at $2.1 billion (25%), and 1 more; 4 of 4 grew against the year before (its annual report).

From the record

Zimmer Biomet Holdings, Inc.'s newest year against its own record: revenue of $8.2 billion in fiscal 2025 came in 1.9% above the $8.1 billion its prior three years' pace pointed to (top 40% of its family); net income of $705 million against a prior three-year average of $720 million (top 50%); a net margin of 8.6% against 9.7% before (bottom 41%) (its annual reports).